Rafael Holdings, Inc. Class B (RFL): Price and Financial Metrics
GET POWR RATINGS... FREE!
RFL Stock Summary
- For RFL, its debt to operating expenses ratio is greater than that reported by only 0.44% of US equities we're observing.
- With a year-over-year growth in debt of -100%, RAFAEL HOLDINGS INC's debt growth rate surpasses just 0% of about US stocks.
- As for revenue growth, note that RFL's revenue has grown -138.73% over the past 12 months; that beats the revenue growth of just 0.35% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to RAFAEL HOLDINGS INC, a group of peers worth examining would be VLD, IVAC, OUST, ALGM, and CERS.
- RFL's SEC filings can be seen here. And to visit RAFAEL HOLDINGS INC's official web site, go to www.rafaelholdings.com.
RFL Valuation Summary
- In comparison to the median Healthcare stock, RFL's price/earnings ratio is 115.49% lower, now standing at -3.5.
- RFL's price/earnings ratio has moved down 444.8 over the prior 61 months.
Below are key valuation metrics over time for RFL.
RFL's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- RFL has a Quality Grade of D, ranking ahead of 24.16% of graded US stocks.
- RFL's asset turnover comes in at 0.027 -- ranking 59th of 63 Real Estate stocks.
- 500 - Internal server error
The table below shows RFL's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
RFL Stock Price Chart Interactive Chart >
RFL Price/Volume Stats
|Current price||$1.61||52-week high||$2.91|
|Prev. close||$1.74||52-week low||$1.60|
|Day high||$1.75||Avg. volume||60,536|
|50-day MA||$2.07||Dividend yield||N/A|
|200-day MA||$2.00||Market Cap||39.40M|
Rafael Holdings, Inc. Class B (RFL) Company Bio
Rafael Holdings, Inc., through its subsidiary, manufactures metabolic oncology drugs to treat cancer. The company also owns and operates real estate properties. The company was incorporated in 2017 and is based in Newark, New Jersey. Rafael Holdings, Inc. operates as a subsidiary of IDT Corporation
Most Popular Stories View All
RFL Latest News Stream
|Loading, please wait...|
RFL Latest Social Stream
View Full RFL Social Stream
Latest RFL News From Around the Web
Below are the latest news stories about RAFAEL HOLDINGS INC that investors may wish to consider to help them evaluate RFL as an investment opportunity.
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. “We are pleased to have successfully completed the sale of our real estate asset located in Newark NJ during the first quarter of fiscal 2023, and believe that our strong balance sheet provides us the opportunity to focus on strategic business development efforts. Our goal is to acquire, in-license or invest
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
NEWARK, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute in order to reduce spending and focus on exploring strategic opportunities to invest in, acquire, or in-license clinical stage assets. As of July 31, 2022, the Company held cash, cash equivalents and marketable securities of $63.2 million, and subsequently received $33 million in net p
Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
NEWARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), a holding company with interests in clinical and early-stage pharmaceutical companies, today reported its financial results for the three and twelve months ended July 31, 2022. The Company is accelerating its focus on exploring strategic opportunities to further enhance value while continuing to develop and evaluate its pipeline. “With the net proceeds of $33 million received in August 2022 from the sale of real e
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancerCranbury, Sept. 28, 2022 (GLOBE NEWSWIRE) -- September 28, 2022 - Cornerstone Pharmaceuticals, Inc., a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613® (devimistat) in combination with chemoradiation for the treat
Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage
NEWARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today announced that it has closed on the sale of the building housing its headquarters to affiliates of The Sinai Equity Group. The building located at 520 Broad Street in Newark, New Jersey and an associated 800-car public garage sold for a total purchase price of $49.4 million. Rafael Holdings expects net proceeds of approximately $33 mill
RFL Price Returns
Continue Researching RFLWant to see what other sources are saying about Rafael Holdings Inc's financials and stock price? Try the links below:
Rafael Holdings Inc (RFL) Stock Price | Nasdaq
Rafael Holdings Inc (RFL) Stock Quote, History and News - Yahoo Finance
Rafael Holdings Inc (RFL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...